PALO ALTO, Calif., Nov. 22 /PRNewswire-FirstCall/ -- Telik, Inc. announced that company management will provide a corporate update at the Lazard Capital Markets Life Sciences Conference in New York City on November 30, 2005 at 9:30 am Eastern time. A live webcast of the presentation will be available via the Telik website, www.telik.com, and an archived replay of the webcast will be available on the Telik website through December 7, 2005.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA(TM) (TLK286), a tumor-activated small molecule product candidate. TELCYTA is in three Phase 3 registration trials in advanced ovarian and non- small cell lung cancer. A second drug development candidate, TELINTRA(TM) (TLK199), is in Phase 2 clinical development in myelodysplastic syndrome. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
Telik, Inc.
CONTACT: Carol D. DeGuzman, Senior Director, Corporate Communications, ofTelik, Inc., +1-650-845-7728 or cdeguzman@telik.com
Web site: http://www.telik.com/
